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Abstract
Background: Bronchiolitis imposes the largest health care burden on non-elective paediatric hospital admissions
worldwide, with up to 15 % of cases requiring admission to intensive care. A number of previous studies have
failed to show benefit of pharmaceutical treatment in respect to length of stay, reduction in PICU admission rates
or intubation frequency. The early use of non-invasive respiratory support devices in less intensive scenarios to
facilitate earlier respiratory support may have an impact on outcome by avoiding progression of the disease
process. High Flow Nasal Cannula (HFNC) therapy has emerged as a new method to provide humidified air
flow to deliver a non-invasive form of positive pressure support with titratable oxygen fraction. There is a lack
of high-grade evidence on use of HFNC therapy in bronchiolitis.
Methods/Design: Prospective multi-centre randomised trial comparing standard treatment (standard subnasal
oxygen) and High Flow Nasal Cannula therapy in infants with bronchiolitis admitted to 17 hospitals emergency
departments and wards in Australia and New Zealand, including 12 non-tertiary regional/metropolitan and 5 tertiary
centres. The primary outcome is treatment failure; defined as meeting three out of four pre-specified failure criteria
requiring escalation of treatment or higher level of care; i) heart rate remains unchanged or increased compared to
admission/enrolment observations, ii) respiratory rate remains unchanged or increased compared to admission/
enrolment observations, iii) oxygen requirement in HFNC therapy arm exceeds FiO2 ≥ 40 % to maintain SpO2 ≥
92 % (or ≥94 %) or oxygen requirement in standard subnasal oxygen therapy arm exceeds >2L/min to maintain
SpO2 ≥ 92 % (or ≥94 %), and iv) hospital internal Early Warning Tool calls for medical review and escalation of
care. Secondary outcomes include transfer to tertiary institution, admission to intensive care, length of stay,
length of oxygen treatment, need for non-invasive/invasive ventilation, intubation, adverse events, and cost.
Discussion: This large multicenter randomised trial will allow the definitive assessment of the efficacy of HFNC
therapy as compared to standard subnasal oxygen in the treatment of bronchiolitis.
Trial registration: The trial is registered with the Australian and New Zealand Clinical Trials Registry
ACTRN12613000388718 (registered on 10 April 2013).
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Background
Bronchiolitis, an acute lower airway lung disease caused
by respiratory viruses, is the most common reason
worldwide for infants <1 year of age to be admitted to
hospital. Data from the USA shows that the health care
burden from infants hospitalised with bronchiolitis is
conservatively estimated to be US$1.73 billion per year
[1, 2]. In Australia, approximately 11,000 infants with
bronchiolitis require hospital admission each year, of
which 1254 (12 %) were admitted to a Paediatric Inten-
sive Care Unit (PICU) in 2013. This equates to 17.1 % of
all non-elective PICU admissions, imposing a heavy re-
source burden (http://www.anzics.com.au/Pages/CORE/
CORE-Reports.aspx). Numerous studies over the last
three decades have investigated the role of various medi-
cations in managing infants with bronchiolitis including
adrenaline, steroids, salbutamol/albuterol, and hyper-
tonic saline; none of these studies have definitively
changed the outcome of the disease, the burden on
health care systems, or reduced the number of PICU
admissions [3].
The agreed current approach to management of in-
fants with bronchiolitis in hospitals is focused on oxygen
therapy for hypoxia, respiratory support and the main-
tenance of hydration [4]. Respiratory support has trad-
itionally been the domain of intensive care settings, and
has been provided through an escalation of therapy from
simple oxygen delivery by nasal cannula, to non-invasive
ventilation with Continuous Positive Airway Pressure
(CPAP) and finally to intubation and mechanical ventila-
tion [5–7]. These latter two strategies require highly
skilled staff, are costly, and are associated with a greater
incidence of adverse events including ventilator-induced
lung injury, barotrauma, and potential neurotoxicity
associated with sedation [8].
Over the last decade High Flow Nasal Cannula
(HFNC) therapy has emerged as a new method to pro-
vide respiratory support for bronchiolitis [9]. HFNC
therapy works by delivering an increased volume of air
and oxygen into the nasal passages than standard subna-
sal oxygen therapy, using a higher flow of humidified
and heated gas. These increased flow rates exceed peak
inspiratory flow and thereby result in more efficient de-
livery of oxygen to the terminal airways. Physiological
studies have demonstrated reduced work of breathing
and improved gas exchange [10, 11]. However, the clin-
ical effectiveness of HFNC therapy in bronchiolitis has
only been reported in non-experimental observational
studies, and there is a lack of appropriately powered ran-
domised studies with well-defined clinically meaningful
outcomes [12, 13]. Moreover, the potential impact of
HFNC therapy on healthcare costs related to the man-
agement of infants with bronchiolitis has not been
investigated.
Two previous clinical studies using HFNC therapy in a
non-randomised design have shown a reduction in in-
tubation rates in critically ill infants in the intensive care
setting [14, 15]. Both studies, however, leave the ques-
tion unanswered whether this is due to improved patient
care or indeed to a higher admission rate of less sick pa-
tients. A recent retrospective study showed that HFNC
therapy is similar in effectiveness to nasal CPAP when
used in a Paediatric Intensive Care Unit (PICU) with
25 % of the patients requiring escalation to invasive
ventilation [16]. Another study analysed the outcome
of infants and children presenting to an emergency de-
partment (ED) including a range of diagnoses for re-
spiratory distress [17]. Approximately half of the 498
patients studied presented with bronchiolitis. Infants
with bronchiolitis were the least likely to require in-
tubation in this cohort and most patients responded
to HFNC therapy within the first three hours of HFNC
therapy initiation.
Published reports on the use of HFNC therapy suggest a
very good safety profile, including the fact that patients
rarely require sedation in contrast to mask-delivered non-
invasive ventilation [16]. Pilot studies have thus investi-
gated use of HFNC therapy in general paediatric ward
settings with encouraging results. A pilot study in 61 in-
fants with bronchiolitis using a flow rate of 2 L/kg/min
showed that HFNC therapy can be safely delivered in a
general paediatric ward and that the PICU admission rate
compared to a control group could be significantly re-
duced by 2.5 times [12]. This data suggests a beneficial
role for HFNC therapy, and indicates that this can be
safely implemented in ward settings. However, in view of
the lack of high-grade evidence, there is an urgent need to
perform a large multicentre randomised controlled trial
on use of HFNC in bronchiolitis.
Methods
Study aims
To perform a randomised controlled multicentre trial
(RCT) in infants aged less than 12 months (corrected
age) with clinically diagnosed bronchiolitis comparing
HFNC therapy to standard subnasal oxygen therapy.
The primary outcome is treatment failure of HFNC
therapy or standard subnasal oxygen.
Secondary outcome measures comprise (a) the rate of
transfer of children to higher level care (that is, the rate
of transfer from regional hospitals to tertiary centres and
rate of transfer from tertiary hospitals to their onsite
intensive care unit (ICU) if the primary admission is
to their tertiary hospital); (b) length of stay in hospital
and (c) health care costs associated with the therapy,
transfer and ICU admission (including intubation
rates), and overall length of stay; (d) length of oxygen
therapy; (e) and measurement of adverse side effects.
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We hypothesise that HFNC therapy will have a lower
failure proportion, reduced transfer rate, reduced
length of stay, and lower health care costs associated
with the treatment, in comparison to standard subna-
sal oxygen.
Study design and settings
Design
Open label, non-blinded multi-centre, randomised con-
trolled trial comparing respiratory support and oxygen
delivery via HFNC therapy versus standard subnasal
oxygen therapy in infants (corrected age) to 12 months
of age admitted to hospital with bronchiolitis.
Setting
Emergency departments and general paediatric wards of
17 hospitals in Australia and New Zealand, including 12
non-tertiary regional/metropolitan and 5 tertiary centres.
Eight hospitals will have access to on-site intensive care
units that cater for infants less than 12 months of age.
Patients will be recruited in both the ED and general
paediatric wards of these hospitals.
Ethical consideration and delayed consent
The study has ethical approval for delayed consent for
all except one of the participating centres, as Ethics
within their State does not accept delayed consent under
the Interstate Mutual Acceptance initiative (Children’s
Health Queensland HREC/13/QRCH/93, New Zealand
Health and Disability Ethics Committees HDEC/15/
CEN/46). Informed consent will be sought from the par-
ent or guardian of the infant by the Research Nurse,
Study Coordinator, or relevant clinician as soon as pos-
sible once the infant has been stabilised and the parent/
guardian has had time to adjust to the emergency envir-
onment. The parents/guardians can withdraw at any
time during the study, the information already collected
will be retained, to ensure the results of the study can be
properly evaluated.
The trial is overseen by a steering committee respon-
sible for the ethical and rigorous conduct of the trial in
both Australia and New Zealand. Governance approval
has been obtained from all study sites. A Data Safety
and Adverse Event Monitoring Committee has been
appointed with membership independent from the con-
duct of the trial.
Case selection
Infants meeting all inclusion and exclusion criteria will
be identified at triage in all EDs. This includes identify-
ing all patients <12 months of age with respiratory
symptoms and an oxygen requirement (less than 92 %
saturation for tertiary centres and less than 94 % satur-
ation for metropolitan and regional centres). Patients
who are admitted to the paediatric ward without an oxy-
gen requirement on admission but later meet these in-
clusion criteria are to be recruited into the study from
the ward environment.
Definitions
All infants aged 0-12 months with symptoms of bron-
chiolitis (as defined by the American Academy of
Pediatrics) - symptoms and signs of respiratory distress
and oxygen requirements are eligible [18]. Bronchiolitis
is defined as signs and symptoms of respiratory distress
associated with symptoms of a viral respiratory tract in-
fection (cough, runny nose, blocked nose, tachypnoea,
recessions, nasal flaring, and cyanosis) [3]. Oxygen re-
quirement in room air is defined according to the World
Health Organisation recommendation, if transcutaneous
haemoglobin oxygen saturation (SpO2) is <94 % in room
air [19–21]. Six participating tertiary centres in our
study have a lower threshold of < 92 % as their standard
practice of care. In these sites a threshold of < 92 % was
accepted in the randomised design, different saturation
thresholds in different centres will be balanced through
randomisation across all sites.
Inclusion criteria are infants with a clinical diagnosis of
bronchiolitis less than 12 months corrected age (≥ 37
weeks post-conceptional age) with an oxygen requirement
in room air of SpO2 < 92 % for tertiary centres and <94 %
for regional and metropolitan centres.
Exclusion criteria include those infants with urgent
need for respiratory support ( i.e. non-invasive or inva-
sive ventilation or low level of consciousness, apnoea),
cyanotic heart disease, basilar skull fracture, upper air-
way obstruction, craniofacial malformations and infants
who are already on home oxygen therapy.
Primary outcome definition
The primary outcome is the proportion of infants in
each group with treatment failure. Treatment failure of
either standard subnasal oxygen or HFNC therapy arm
is defined as meeting three out of four specified failure
criteria requiring escalation of treatment or higher level
of care such as high acuity or intensive care. Prior to es-
calation of care 2 to 3 hours of observing the infant in
an undisturbed environment is suggested. This time
frame was based on the pilot study whereby it was
clearly identified that the infants who are going to fail
will do so within 2 to 3 hours [12]. In the pilot study,
those who failed HFNC therapy had unchanged or in-
creasing heart rate and respiratory rate, or worsening
SpO2. Clinicians are asked to wait 2 to 3 hours prior to
escalation of care, however, if they are more concerned,
their clinical judgement can override the protocol if a
decision is made to escalate care.
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Treatment failure of either standard subnasal oxygen
or HFNC therapy arm is defined if three of the four fol-
lowing criteria are met and an escalation of treatment or
level of care is required
a.) heart rate remains unchanged or increased
compared to admission/enrolment observations,
b.) respiratory rate remains unchanged or increased
compared to admission/enrolment observations,
c.) oxygen requirement in HFNC therapy arm exceeds
FiO2 ≥ 40 % to maintain SpO2 ≥ 92 % (or ≥94 %) or
oxygen requirement in standard subnasal oxygen
therapy arm exceeds >2L/min to maintain SpO2 ≥
92 % (or ≥94 %)
d.)hospital internal Early Warning Tool calls for
medical review and escalation of care.
The study design utilises a composite primary end-
point of treatment failure, which has previously been
used in a RCT of HFNC therapy vs. CPAP post extuba-
tion in neonates conducted in Australia [22].
Secondary outcome definition
Secondary outcomes are defined as (a) the proportion of
infants requiring transfer to higher acuity care, which in-
cludes admission to an on-site paediatric intensive care
or transfer to a tertiary hospital; (b) length of hospital
stay, including intensive care length of stay and (c) in-
tubation rates; (e) associated health care costs for the
respective therapy; (f ) length of oxygen therapy and;
(g) adverse events.
Randomisation process
The enrolment/randomisation process has been success-
fully tested in the previous pilot study. Randomisation
will be achieved by an opaque envelope in sequential
order with an allocated infant ratio of 1:1. A computer-
based randomisation will be used to allocate infants 1:1
per site. Randomisation can occur at admission or at any
time during hospital stay when an oxygen requirement
develops.
Treatment arms
Control
The infant that is randomised to the Control arm will be
placed on standard subnasal cannula with oxygen flows
up to a maximum of 2L/min according to local hospital
practice to maintain SpO2 between 92-98 % (94-98 %).
This may or may not be humidified oxygen, and will be
according to current individual hospital guidelines. Oxy-
gen flows should be administered below 2L/min to com-
mence with and increased as required to maintain
SpO2 ≥ 92 % (≥ 94 %).
HFNC therapy
The infant that is randomised to the HFNC therapy arm
with SpO2 85-91 % (85-93 %) will be placed on high
flow at 2L/kg/min (up to a maximum of 25 L/min) in
room air equating to a fraction of inspired oxygen of
21 % (FiO2). They will remain on room air for a mini-
mum of 10 minutes whilst monitoring SpO2. If SpO2
starts to increase and stabilise at ≥92 % (≥94 %) then
continue on room air of 21 %. If SpO2 has not altered
or improved then the FiO2 will be slowly increased to
maintain SpO2 ≥ 92 % (≥94 %). The infant that is ran-
domised to the HFNC therapy arm with SpO2 < 85 %
will commence on high flow with FiO2 slowly increas-
ing to achieve SpO2 ≥ 92 % (≥94 %).
Other interventions/therapies/nutrition
The use of any medications such as steroids, antibiotics,
antipyretics, bronchodilators and hypertonic saline is at
the discretion of the attending clinicians and not pre-
scribed in the protocol. These interventions will be re-
corded in the clinical research form (CRF). Feeding in
standard subnasal cannula oxygen therapy is not pre-
scribed and clinicians can choose to administer continu-
ous or bolus feeds or use intravenous fluids. However, in
the HFNC therapy intervention arm a nasogastric tube
will be inserted, the stomach must be vented at 4 hour
intervals, and no oral feeding will be allowed unless in
stable weaning phase. Feeding rate should be prescribed
as per individual hospital policy using nasogastric (bolus
or continuous feeds).
The nursing ratio for both arms will remain according
to the standard current ward management already
present and as per usual hospital protocol. The nurse/
patient ratio is important to maintain, to ensure that in-
fants with the same level of illness do not get increased
nursing care due to being on one type of therapy over
another. Clinical documentation will be achieved according
to individual hospital standards. Admission criteria to in-
tensive care and triggering of medical review (use of early
warning tool) will also follow individual hospital rules.
Choice of 2L/kg/min flow rate
Studies have demonstrated that the maximal inspiratory
flow that a healthy infant achieves during regular breath-
ing is 0.8 L/kg/min for each breath. An unwell infant such
as an infant with bronchiolitis, generates a higher in-
spiratory flow which can be as high as 1.0-1.6 L/kg/min
[10, 23]. The aim of HFNC therapy is to match this
maximal inspiratory flow generated by the infant, so
that no additional air is entrained around the nasal
prongs. For this purpose a safety margin of 2 L/kg/min
is given, to ensure adequate flow is provided for these
infants.
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There is a population of larger babies less than 12
months of age and the HFNC therapy for this study will
not exceed 25L/min. This is based on using the infant’s
ideal weight rather than actual weight as a measure of
how to deliver the flow for the larger babies.
Weaning
Responders in the standard subnasal oxygen therapy
arm will be weaned from 2 L/min or less if SpO2 re-
mains stable at 92-98 % (94-98 %). Infants will be
weaned to room air and nasal cannula removed once an
infant is able to maintain saturations in the target range
on room air for at least four hours. SpO2 to be maintained
within 92-98 % (94-98 %) at all times and if <92 % (<94 %),
then oxygen flow will increase again until SpO2 within
92-98 % (94-98 %). Once SpO2 is stabilised, weaning
will recommence, using the same parameters.
For responders in the HFNC therapy arm, flow rates
will be kept at 2L/kg/min, while FiO2 is decreased. Flow
rates are not to be weaned and are to be maintained at
2L/kg/min until HFNC therapy is ceased and turned off
completely. Once FiO2 has reached 21 % with SpO2
maintained between 92-98 % (94-98 %) for four hours
the high flow off is turned off and the nasal cannula are
removed.
Escalation of therapy after treatment failure (primary
outcome)
Once failure criteria are met, escalation of treatment
may be from standard subnasal oxygen therapy to HFNC
therapy and/or escalation to non-invasive ventilation or
intubation and mechanical ventilation in intensive care.
It is at the discretion of the attending physician to man-
age and treat the ongoing care. If escalation from stand-
ard subnasal oxygen to HFNC therapy occurs then the
same protocol shall be applied as in HFNC therapy arm.
However, at any time during the study the physician can
override and escalate care. This aspect of clinical reason-
ing to escalate will be captured in the data set and is
defined as follows: i.) increased work of breathing re-
quiring escalation of respiratory support, ii.) decreased
conscious level, iii.) deterioration of cardiovascular func-
tion with impaired peripheral perfusion, iv.) clinical
judgment of attending (senior) medical officer triggers
escalation of treatment and care.
With any escalation of treatment the nurse/patient ra-
tio will be captured to perform cost assessments on re-
quired level of care at the time of escalation and
thereafter.
Clinical observations
SpO2 will be measured at enrolment in room air. If the
infant has had oxygen administered in the ambulance,
then it will be ceased and SpO2 assessed a few minutes
later to ascertain if the infant meets the inclusion criteria
of SpO2 < 92 % (<94 %). Once this inclusion criteria has
been established, respiratory rate, respiratory effort and
heart rate will be measured at enrolment. Observations
thereafter will be according to current hospital protocol
within either the ED or general paediatric ward.
At each set of observations, the following parameters
will be documented: SpO2, heart rate, respiratory rate,
respiratory effort, oxygen/FiO2 administered, flow rate
of high flow therapy and at frequent intervals the
temperature and blood pressure will be monitored ac-
cording to standard hospital guidelines.
Complications recorded will include episodes of ap-
noea and bradycardia (lasting more than 20 seconds); all
episodes where the SpO2 was recorded <92 % (94 %)
and adverse outcomes such as pneumothoraces or
deaths.
Laboratory investigations
Laboratory investigations are not mandated for the trial.
However it is recommended that all enrolled patients
have screening for respiratory viruses using nasopharyn-
geal aspirate completed to provide data on the various
viruses amongst the recruited patients. The screening
will occur at the discretion of the managing physician.
Time frame
It is predicted that patient enrolment will occur over a
period of three years. Individual participant study in-
volvement will cease at death or discharge home.
Healthcare cost analysis
A within-trial economic evaluation will be undertaken
from the health care provider perspective using a cost-
minimisation approach, to compare the cost of providing
HFNC therapy to that of standard subnasal oxygen ther-
apy. This approach assumes a reasonable and equivalent
clinical outcome at the point of discharge to home.
Resources to be measured and costed will include the
number of transfers between hospitals, length of stay
(in PICU and/or non-intensive stay), and resources related
to use of the intervention (HFNC therapy or standard
subnasal oxygen therapy). Costs will be assigned using
standard costing sources [24]. The Australian refined
diagnostic-related groups (AR-DRG) will be used to indi-
cate the costs associated with each hospital admission, ad-
justed for length of stay in hospital and in PICU. The New
Zealand centres health care costs will be analysed sep-
arately and sensitivity analysis for the different health
care system will be performed. Parametric (e.g. ANCOVA)
and non-parametric bootstrapping techniques will be
employed to compare the costs between groups, and to
estimate a confidence interval around the mean difference
[25]. It is anticipated that HFNC therapy will be cost
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saving to the health system. The cost comparison will in-
form recommendations on adopting HFNC therapy for
the management of bronchiolitis in clinical practice.
Sample size, power and statistical methods
Sample size
In 2011 there were 478 eligible patients admitted to 4 of
8 pilot hospitals (Queensland), of which 80 required
transfer to a tertiary paediatric centre (16.7 %). Assum-
ing a conservative baseline rate of failure of standard
therapy (need for transfer to a specialist paediatric
centre or PICU admission) of 10 %, a 50 % relative re-
duction to 5 % with a power of 90 % and type I error of
0.05, 582 participants per group are required, resulting
in a total sample size of 1164 patients. An attrition rate
of approximately 10-20 % is estimated, which gives an
overall sample size of 1400.
Data analysis
Descriptive statistics will be utilised to report on the
baseline characteristics of the total study cohort, as well
as by site. The primary outcome measure investigating
clinical treatment failure will be analysed using test of
two proportions, and will be reported as the difference,
95 % confidence interval and p-value. The secondary
outcome measure investigating length of stay will likely
be non-normally distributed, and as such will be ana-
lysed using a Mann-Whitney U test; if it is normally dis-
tributed independent samples t-test will be used.
Analysis of secondary outcomes includes both compari-
sons of measurements and proportions, using confidence
intervals of differences as the major method of presenta-
tion where possible. A logistic regression analysis will be
used to identify risk factors. All analyses will be by
intention-to-treat. A per protocol analysis will be under-
taken as a secondary analysis. Pre-specified sub-groups
include; ex-preterm infants, infants with congenital heart
defect, infants less than 3 months of age (corrected), in-
fants less than 6 months of age (corrected), infants pre-
senting to tertiary sites, infants presenting to secondary
sites. Statistical significance will be set at the 0.05 level.
No interim analysis will occur and no stopping rules
were defined.
Adverse events and monitoring/reporting
Data safety monitoring
An external data safety monitoring board has been
established. All adverse events and experiences by either
staff or parent/guardian will be reported on the CRF
provided for each patient and the local Principal Investi-
gator notified who will in turn notify the Chief Investiga-
tor. A serious adverse event (SAE) is defined as any
event that is fatal, life-threatening, permanently disab-
ling, incapacitation or prolongs a hospital stay.
Reporting SAE
SAEs will be reported within 24 hrs by telephone to the
local Principal Investigator who in turn will notify the
Chief Investigator. The local site investigator will report
the SAE to their local ethics committee within 48 hours
(or in accordance with local ethics committee
regulations).
Limitations
As a non-blinded trial there is the potential for the in-
vestigator to unintentionally introduce measurement or
reporting bias because further knowledge of the study
and treatment allocation could influence the clinicians’
decision-making. The end points can be seen as subject-
ive and we cannot alter the medical and nursing staff ’s
opinion at certain points in the trial. As an example,
some patients may be seen as not responding to enrolled
arm treatment at one centre or on one shift whereas an-
other centre or the next shift of staff may view this dif-
ferently. It is not possible in this trial to blind the
investigators or treating physicians.
Current status of trial
The study enrolment has commenced, and are expecting
all 17 sites to be recruiting by end of July 2015.
Sites involved in the study include:
Australia:
Queensland:
Ipswich Hospital, Gold Coast University Hospital,
Caboolture Hospital, Nambour Hospital, Logan Hospital,
Redland Hospital, Redcliffe Hospital, The Prince Charles
Hospital, Toowoomba Hospital, Townsville Hospital,
Lady Cilento Children’s Hospital
New South Wales:
The Tweed Hospital
Victoria:
Royal Children’s Hospital Melbourne
Monash Health
ACT:
Canberra Hospital
New Zealand:
Starship Children’s Health
KidzFirst, Middlemore Hospital
Discussion
This large multicentre randomised trial will allow the
definitive assessment of the efficacy of high flow nasal
cannula therapy as compared to standard subnasal oxy-
gen in preventing treatment failure and the need for es-
calation of respiratory support. This study will in
addition provide a unique insight into the adverse events
profile of high flow nasal cannula therapy when used
outside the intensive care setting and the epidemiology
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of the moderate to severe end of the spectrum of
bronchiolitis.
Time plan
To date (July 2015), 380 patients have been recruited for
the planned 1400 patients with recruitment to be com-
pleted in 2017.
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